• Humacyte flagged interim Phase 3 V012 results for its acellular tissue engineered vessel in female dialysis-access patients.
• Data have not been presented yet; a late-breaking oral presentation is scheduled for Oct. 22, 2026 at ASN Kidney Week.
• The randomized trial compares the device with autogenous arteriovenous fistula to assess whether it offers a better access option for women.
• The readout supports a planned supplemental BLA to expand the Symvess label into hemodialysis arteriovenous access, targeted this quarter.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Humacyte Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610120800PRIMZONEFULLFEED9843143) on October 12, 2026, and is solely responsible for the information contained therein.